Published in Biomed Pharmacother on May 01, 2002
Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol (2007) 0.93
Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression? Oncologist (2011) 0.82
Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med (1999) 3.18
Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol (1999) 2.25
Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. Blood (1997) 1.96
Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res (1999) 1.85
Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol (2001) 1.55
Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J Natl Cancer Inst (1993) 1.54
Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol (2001) 1.52
Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis (2003) 1.46
Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia (2007) 1.23
Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int Immunol (2000) 1.18
Granulocyte-colony stimulating factor and lipopolysaccharide regulate the expression of interleukin 8 receptors on polymorphonuclear leukocytes. J Biol Chem (1995) 1.13
Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood (1996) 1.09
Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood (2000) 1.06
Murine macrophages express abundant insulin-like growth factor-I class I Ea and Eb transcripts. Endocrinology (1993) 1.01
Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol (2009) 1.01
Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant (2005) 1.00
Interleukin-8 receptor beta. The role of the carboxyl terminus in signal transduction. J Biol Chem (1995) 1.00
Regulation of CCR2 chemokine receptor mRNA stability. J Leukoc Biol (1997) 0.98
Regulation of nitric-oxide synthase mRNA expression by interferon-gamma and picolinic acid. J Biol Chem (1994) 0.95
Blood levels of organochlorines before and after chemotherapy among non-Hodgkin's lymphoma patients. Cancer Epidemiol Biomarkers Prev (2000) 0.94
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol (2011) 0.92
Functional analysis of the lymphotoxin-beta promoter. Sequence requirements for PMA activation. J Immunol (1996) 0.90
Interferon-gamma inhibits macrophage insulin-like growth factor-I synthesis at the transcriptional level. Mol Endocrinol (1995) 0.88
Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia (2012) 0.87
Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients. Bone Marrow Transplant (2012) 0.84
Induction of TLR4-dependent CD8+ T cell immunity by murine β-defensin2 fusion protein vaccines. Vaccine (2011) 0.84
The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. Ann Oncol (1991) 0.83
Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine. J Cancer Res Clin Oncol (2001) 0.80
Follicular lymphoma: a model of lymphoid tumor progression in man. Ann Oncol (1991) 0.79
B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions. Immunol Rev (1999) 0.79
Immunotherapy of multiple myeloma. Semin Hematol (2001) 0.79
Competitive reverse transcriptase-polymerase chain reaction using a synthetic internal RNA standard to quantitate transcripts for leukocyte-derived hormones. Neuroimmunomodulation (1994) 0.78
Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor. J Natl Cancer Inst (1995) 0.78
Molecular identification of two types of interleukin-1 receptors in the murine pituitary gland. J Neuroendocrinol (1993) 0.78
H-2-linked resistance to mastocytoma in male mice: immune response to a histocompatibility antigen on the X chromosome. Science (1983) 0.78
Designer cancer vaccines are still in fashion. Nat Med (2000) 0.77
Evidence for involvement of the H-2Kb and I-Ab genes in hybrid resistance to P815-X2. Immunogenetics (1981) 0.77
Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP). Ther Immunol (1995) 0.77
Development of vaccine strategies for the treatment of B-cell malignancies. Cancer Invest (1997) 0.77
Serum BCL2/IGH DNA in follicular lymphoma patients: a minimal residual disease marker. Leuk Lymphoma (2000) 0.75
Mechanisms of resistance against B-cell malignancies induced by vaccination against the immunoglobulin receptor: the case for T-cell immunity. Cancer Treat Res (1999) 0.75
The use of idiotype as a target for clinical immunotherapy of B cell malignancies. Cancer Chemother Biol Response Modif (2001) 0.75
Immune response to the H-X antigen on P815-X2. I. Recombinant inbred strain analysis and lack of effect of castration. Immunogenetics (1984) 0.75
H-2 gene control of resistance to P815-X2 mastocytoma. Cancer Res (1983) 0.75
MACOP-B +/- radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford results according to prognostic indices. Cancer (1993) 0.75